SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration
International Journal of Oncology · 23.01.2024 · 64 (3)
DOI: 10.3892/ijo.2024.5618 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Oncology, online erschienen am 23.01.2024. Verfasst von Shihao Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, MicroRNAs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Solute carrier organic anion transporter family member 4A1 (SLCO4A1) is a membrane transporter protein. The role of this molecule in non‑small cell lung cancer (NSCLC) remains unclear. Bulk sequencing was carried out using early‑stage NSCLC tissues with lymph node metastasis to identify SLCO4A1 that influences NSCLC cell proliferation, metastasis and prognosis. The in vitro functional assays carried out included the following: Cell Counting Kit‑8, plate colony formation, Transwell and wound healing assays. The molecular techniques used included reverse transcription‑quantitative PCR, western blotting and immunohistochemistry. The present study revealed the role of SLCO4A in NSCLC. SLCO4A1 was found to be expressed at high levels in NSCLC tissues and cells, and promotes cell proliferation, migration and invasion. Kaplan‑Meier survival analysis indicated that patients with NSCLC and high expression of SLCO4A1 had a poor prognosis. SLCO4A was revealed to regulate the expression of the proliferation‑related proteins Ki‑67 and PCNA, and that of the extracellular matrix proteins vimentin and E‑cadherin. Mechanistically, SLCO4A1 may affect the MAPK signaling pathway to promote NSCLC cell proliferation, migration and invasion. In addition, bioinformatics analysis demonstrated a strong association between SLCO4A1 and tumor infiltrating immune cells, highlighting its critical role in immune therapies such as immune checkpoint inhibitor treatment of patients with NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Zitieren
APA
Li, S., Li, Z., Huang, L., Geng, Z., Li, F., Wu, B., Sheng, Y., Xu, Y., Li, B., Xu, Y., Gu, Z., & Qi, Y. (2024). SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration. International Journal of Oncology, 64(3). https://doi.org/10.3892/ijo.2024.5618
Vancouver
Li S, Li Z, Huang L, Geng Z, Li F, Wu B, et al. SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration. International Journal of Oncology. 2024;64(3). doi:10.3892/ijo.2024.5618
BibTeX
@article{Li2024,
author = {Li, Shihao and Li, Zihao and Huang, Lan and Geng, Zhenyang and Li, Feng and Wu, Bin and Sheng, Yinliang and Xu, Yifan and Li, Bowen and Xu, Yiming and Gu, Zhuoyu and Qi, Yu},
title = {SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration},
journal = {International Journal of Oncology},
year = {2024},
volume = {64},
number = {3},
doi = {10.3892/ijo.2024.5618}
}
EUVIMED